Loading...

Medivir AB (publ)

0GP7.L•LSE
Healthcare
Medical - Pharmaceuticals
£1.76
£-0.02(-0.90%)

Medivir AB (publ) (0GP7.L) Stock Overview

Explore Medivir AB (publ)’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.7/100

Key Financials

Market Cap182.6M
P/E Ratio-4.51
EPS (TTM)$-1.58
ROE-0.38%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$2.25

0GP7.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Medivir AB (publ) (0GP7.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 22.30, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of $2.25.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.51 and a market capitalization of 182.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

22.30RSI (14)
-0.09MACD
39.20ADX
Stats data is not available for 0GP7.LStats details for 0GP7.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 0GP7.LAnalyst Recommendations details for 0GP7.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

CEO

Jens Lindberg

Employees

10

Headquarters

Lunastigen 5, Huddinge

Founded

2023

Frequently Asked Questions

;